Manufacturers of Some Diabetes Drugs to Strengthen Warning on Heart Failure Risk
After a review of postmarketing adverse event reports, FDA determined that an updated label with a boxed warning on the risks of heart failure was needed for the entire thiazolidinedione class of antidiabetic drugs.